NCT02783625 2025-06-03Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasMemorial Sloan Kettering Cancer CenterPhase 1 Active not recruiting114 enrolled
NCT03703375 2024-07-08Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCelgenePhase 3 Active not recruiting93 enrolled 19 charts